PubMed Central (PMC) Search Page
Table representation of search results timeline featuring number of search results per year.
| Year | Number of Results |
|---|---|
| 2008 | 1 |
| 2009 | 3 |
| 2010 | 3 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2015 | 2 |
| 2016 | 11 |
| 2017 | 28 |
| 2018 | 15 |
| 2019 | 27 |
| 2020 | 48 |
| 2021 | 158 |
| 2022 | 124 |
| 2023 | 49 |
| 2024 | 1 |
| 2026 | 0 |
-
Publication date
-
-
Publication stage
These filters represent the three primary types of content included in the PMC archive: 1) content published in a scholarly journal 2) peer-reviewed author manuscripts accepted for publication in a journal and 3) preprint versions of articles collected through the NIH Preprint Pilot, made public prior to peer review
-
-
Collections
The PMC Open Access Subset includes journal articles and preprints that are made available under license terms that allow reuse. Historical back issues refers to digitized content from print journals made available in PMC through the Biomedical Journal Digitization Projects.
-
"fsg selective deposit"[Filter]
The embargo is the time during which the publisher retains exclusive rights to distribute articles. Those articles are made freely available on the PMC website after the embargo period has ended. Citations for articles under an embargo period will still display in the PMC results list by default. Choose “Exclude” to prevent embargoed articles from displaying in your results.
-
The roots of (in)equity in precision medicine: gaps in the discourse.
- Green S, Prainsack B, Sabatello M.
- Per Med. 2023 Dec 13;21(1):5-9. doi: 10.2217/pme-2023-0097.
- PMCID: PMC10784620
Green S, et al.Per Med. 2023.PMCID: PMC10784620 -
Antiviral evaluation of 1,4-disubstituted-1,2,3-triazole derivatives against Chikungunya virus.
- Rabelo VW, da Silva VD, Sanchez Nuñez ML, Dos Santos Corrêa Amorim L, Buarque CD, Kuhn RJ, Abreu PA, Nunes de Palmer Paixão IC.
- Future Virol. 2023 Oct 25;18(13):865-880. doi: 10.2217/fvl-2023-0142.
- PMCID: PMC10636642
Rabelo VW, et al.Future Virol. 2023.PMCID: PMC10636642 -
Extracting high-quality RNA from formaldehyde-fixed naturally aged neuromusculoskeletal tissues.
- Thompson SD, Pichika R, Lieber RL, Lavasani M.
- Biotechniques. 2024 Feb 9;76(4):153-160. doi: 10.2144/btn-2023-0092.
- PMCID: PMC10988388
Thompson SD, et al.Biotechniques. 2024.PMCID: PMC10988388 -
Comparison of colorimetric, spectroscopic and electrochemical techniques for quantification of hydrogen sulfide.
- Mhatre S, Rai A, Ali H, Patil A, Singh N, Verma R, Auden J, Chandler C, Dash A, Opere C, Singh S.
- Biotechniques. 2023 Dec 7;76(2):71-80. doi: 10.2144/btn-2023-0075.
- PMCID: PMC10910492
Mhatre S, et al.Biotechniques. 2023.PMCID: PMC10910492 -
Resistance analysis following sotrovimab treatment in participants with COVID-19 during the phase III COMET-ICE study.
- Subramanian S, Schnell G, Iulio JD, Gupta AK, Shapiro AE, Sarkis EH, Lopuski A, Peppercorn A, Aldinger M, Hebner CM, Cathcart AL.
- Future Virol. 2023 Dec 7:10.2217/fvl-2023-0146. doi: 10.2217/fvl-2023-0146.
- PMCID: PMC10705769
Subramanian S, et al.Future Virol. 2023.PMCID: PMC10705769 -
Development of Competency-based Online Genomic Medicine Training (COGENT).
- Haga SB, Chung WK, Cubano LA, Curry TB, Empey PE, Ginsburg GS, Mangold K, Miyake CY, Prakash SK, Ramsey LB, Rowley R, Rohrer Vitek CR, Skaar TC, Wynn J, Manolio TA.
- Per Med. 2022 Nov 23;20(1):55-64. doi: 10.2217/pme-2022-0101.
- PMCID: PMC10291206
Haga SB, et al.Per Med. 2022.PMCID: PMC10291206 -
Antiviral attributes of bee venom as a possible therapeutic approach against SARS-CoV-2 infection.
- Goswami S, Chowdhury JP.
- Future Virol. 2023 Nov 7:10.2217/fvl-2023-0127. doi: 10.2217/fvl-2023-0127.
- PMCID: PMC10630947
Goswami S, et al.Future Virol. 2023.PMCID: PMC10630947 -
Validation of a risk prediction model for COVID-19: the PERIL prospective cohort study.
- Mohammedain SA, Badran S, Elzouki AY, Salim H, Chalaby A, Siddiqui M, Hussein YY, Rahim HA, Thalib L, Alam MF, Al-Badriyeh D, Al-Maadeed S, Doi SA.
- Future Virol. 2023 Nov 7:10.2217/fvl-2023-0036. doi: 10.2217/fvl-2023-0036.
- PMCID: PMC10630949
Mohammedain SA, et al.Future Virol. 2023.PMCID: PMC10630949 -
Oral bemnifosbuvir (AT-527) vs placebo in patients with mild-to-moderate COVID-19 in an outpatient setting (MORNINGSKY).
- Horga A, Saenz R, Yilmaz G, Simón-Campos A, Pietropaolo K, Stubbings WJ, Collinson N, Ishak L, Zrinscak B, Belanger B, Granier C, Lin K, C Hurt A, Zhou XJ, Wildum S, Hammond J.
- Future Virol. 2023 Nov 1:10.2217/fvl-2023-0115. doi: 10.2217/fvl-2023-0115.
- PMCID: PMC10621114
Horga A, et al.Future Virol. 2023.PMCID: PMC10621114 -
In silico identification of deep-sea fungal alkaloids as potential inhibitors of SARS-CoV-2, Delta and Omicron spikes.
- Alanzi AR, Parvez MK, Al-Dosari MS.
- Future Virol. 2023 Oct 26:10.2217/fvl-2023-0102. doi: 10.2217/fvl-2023-0102.
- PMCID: PMC10615363
Alanzi AR, et al.Future Virol. 2023.PMCID: PMC10615363